T. Rowe Price Associates’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

T. Rowe Price Associates’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,500	Closed	-$29K	–	2647
2017 Q3	$29K	Hold	3,500	–	–	﹤0.01%	2561
2017 Q2	$36K	Hold	3,500	–	–	﹤0.01%	2543
2017 Q1	$40K	Hold	3,500	–	–	﹤0.01%	2552
2016 Q4	$44K	Hold	3,500	–	–	﹤0.01%	2529
2016 Q3	$64K	Hold	3,500	–	–	﹤0.01%	2488
2016 Q2	$37K	Sell	3,500 -20	-0.6%	-$393	﹤0.01%	2493
2016 Q1	$66K	Hold	3,520	–	–	﹤0.01%	2457
2015 Q4	$94K	Buy	3,520 +20	+0.6%	+$695	﹤0.01%	2432
2015 Q3	$160K	Hold	3,500	–	–	﹤0.01%	2334
2015 Q2	$113K	Hold	3,500	–	–	﹤0.01%	2445
2015 Q1	$111K	Buy	3,500 +1,500	+75%	+$50.8K	﹤0.01%	2461
2014 Q4	$76K	Hold	2,000	–	–	﹤0.01%	2496
2014 Q3	$53K	Hold	2,000	–	–	﹤0.01%	2518
2014 Q2	$59K	Hold	2,000	–	–	﹤0.01%	2504
2014 Q1	$74K	Buy	2,000 +750	+60%	+$28.4K	﹤0.01%	2455
2013 Q4	$52K	Buy	+1,250	New	+$48.9K	﹤0.01%	2456

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

SFS

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

T. Rowe Price Associates's NAVB Position: Q4 2017 in Review

T. Rowe Price Associates sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2017, closing a stake of 3,500 shares — an estimated $29K sold.

T. Rowe Price Associates first reported a position in NAVB in Q4 2013 and held it in 16 quarters. The position peaked at $160K in Q3 2015. 54 funds tracked by Wall St. Rank hold NAVB as of Q4 2017.

T. Rowe Price Associates reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2017 after selling out during the quarter.
T. Rowe Price Associates sold 3,500 Navidea Biopharmaceuticals Inc. shares in Q4 2017, an estimated $29K.
T. Rowe Price Associates first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2013 and held it in 16 quarters.
T. Rowe Price Associates's Navidea Biopharmaceuticals Inc. position peaked at $160K in Q3 2015.
54 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2017.

Based on T. Rowe Price Associates's 13F filing for Q4 2017, filed 14 Feb 2018.